GK
Gujarat Kidney
Mainboard₹251 Cr issue
+5.26%
Listing gain over issue price
Issue size
₹251 Cr
1 lot at cut-off
₹14,592
Lot size
128shares
Allotment
26 Dec 2025
Listing
30 Dec 2025
Listing performance
Issue price
₹114
Listed at
₹120
Listing-day close
₹104.65
Latest price
₹130.94
Listing gain
+5.26%
Return since listing
+14.86%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
₹1.50
3 observations recorded — too few to plot a trend.
Day-wise premium · 3 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 30 Dec 2025 | ₹1.50 | +1.32% | ₹100 | ₹115.50 | ₹192 |
| 29 Dec 2025 | ₹1.50 | +1.32% | ₹100 | ₹115.50 | ₹192 |
| 28 Dec 2025 | ₹0 | 0.00% | ₹0 | ₹114 | ₹0 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- Listing date
- 30 Dec 2025
- Face value
- ₹2 per share
- Issue price
- ₹114 per share
- Lot size
- 128 shares
- Total issue size
- ₹251 Cr
- Market cap at offer price
- ₹899 Cr
- Promoter holding
- 99.10% → 71.45% pre-issue → post-issue
- ISIN
- INE0V0W01025
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- Nirbhay Capital Services Pvt.Ltd.
- Registered office
- Plot No.1, City Sarve No.1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Gujarat
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 87,73,120 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 128 shares per lot, in multiples, at ₹114
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 128 | ₹14,592 |
| Retail (max) | 13 | 1,664 | ₹1,89,696 |
| S-HNI (min) | 14 | 1,792 | ₹2,04,288 |
| S-HNI (max) | 68 | 8,704 | ₹9,92,256 |
| B-HNI (min) | 69 | 8,832 | ₹10,06,848 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
87,73,120
Anchor portion
₹100 Cr
at ₹114 per share
Valuation and performance
Valuation at offer price
₹114 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 1.85 | 2.74 |
| P/E (×) | 61.62 | 41.61 |
| Price to book (×) | 22.62 | — |
| Market cap | — | ₹899 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 36.61%
- ROCE
- 37.65%
- Debt / equity
- 0.15
- PAT margin
- 23.61%
- EBITDA margin
- 41.12%
- NAV per share
- ₹5.04
- Price to book
- 22.62
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Gujarat Kidney
Gujarat Kidney and Super Speciality Limited, incorporated in December 2019 and converted to public limited in November 2023, is a regional healthcare provider headquartered in Vadodara, Gujarat. On a consolidated basis, the company operates seven multispeciality hospitals and four pharmacies across Gujarat's central region: Gujarat Kidney & Super Speciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand), and Apex Multispeciality & Trauma Center (Bharuch), with a combined total bed capacity of 490 beds, approved bed capacity of 445 beds, and operational bed capacity of 340 beds. The company generates revenue from inpatient and outpatient healthcare services, with a primary focus on kidney disease treatment, multi-speciality services, and trauma care.
Company Analysis
from RHPGujarat Kidney and Super Speciality Limited operates a regional chain of mid-sized multispeciality hospitals providing integrated secondary and tertiary healthcare services across Central Gujarat.
Gujarat Kidney and Super Speciality Limited, incorporated in December 2019 and converted to public limited in November 2023, is a regional healthcare provider headquartered in Vadodara, Gujarat. On a consolidated basis, the company operates seven multispeciality hospitals and four pharmacies across Gujarat's central region: Gujarat Kidney & Super Speciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), M/s. Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand), and Apex Multispeciality & Trauma Center (Bharuch), with a combined total bed capacity of 490 beds, approved bed capacity of 445 beds, and operational bed capacity of 340 beds. The company generates revenue from inpatient and outpatient healthcare services, with a primary focus on kidney disease treatment, multi-speciality services, and trauma care.
healthcare serviceshospital operationsmultispeciality hospitalssecondary caretertiary care
Objects of the Issue
- Proposed acquisition of Parekhs Hospital at Ahmedabad ₹7,700.00 lakhs p.28
- Part-payment of purchase consideration for the already acquired 'Ashwini Medical Centre' ₹1,240.00 lakhs p.28
- Acquisition of additional shareholding in subsidiary 'Harmony Medicare Private Limited' at Bharuch ₹1,078.00 lakhs p.28
- Funding of capital expenditure requirements towards setting up of a new hospital in Vadodara ₹3,009.73 lakhs p.28
- Buying robotics equipment for Gujarat Kidney & Super Speciality hospital at Vadodara location ₹682.50 lakhs p.28
- Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company ₹120.00 lakhs p.28
- Funding inorganic growth through unidentified acquisitions and General Corporate Purposes p.29
- Repayment of borrowings p.68
- Funding capex for new hospital and capital expenditure p.68
- Funding inorganic growth through acquisitions p.67
- General corporate purposes p.67
- Proposed acquisition of Parekhs Hospital Private Limited at Ahmedabad ₹7,700.00 lakhs p.119
- Part payment of purchase consideration for the already acquired hospital Ashwini Medical Centre ₹1,240.00 lakhs p.119
- Acquisition of additional shareholding in subsidiary Harmony Medicare Private Limited at Bharuch ₹1,078.00 lakhs p.119
- Funding capital expenditure for setting up new hospital for women's healthcare in Vadodara ₹3,009.73 lakhs p.119
- Buying robotics equipment for Gujarat Kidney & Super Speciality Hospital Vadodara ₹682.50 lakhs p.119
- Full or part repayment and/or prepayment of outstanding secured borrowings ₹120.00 lakhs p.119
- Funding inorganic growth through unidentified acquisitions and General Corporate Purposes p.119
- Funding capex for the acquisition of Parekhs Hospital Private Limited, Ahmedabad ₹7,900.00 lakhs (aggregate purchase consideration including non-compete fee of ₹100 lakhs) p.212
- General corporate purposes and working capital p.116
- Acquisition of Parekhs Hospital Private Limited at Ahmedabad ₹7,700 lakhs p.221
- Part-payment of purchase consideration for the already acquired Ashwini Medical Centre hospital ₹1,240 lakhs p.214
- Acquisition of Additional Shareholding in subsidiary Harmony Medicare Private Limited at Bharuch p.118
- Medical equipment purchase including Stryker orthopedic robot p.225
- Funding of capital expenditure requirements towards setting up of a new hospital for women's healthcare in Vadodara p.498
Issue Structure
- Total Issue
- Up to 2,20,00,000 Equity Shares of face value of ₹ 2 each aggregating up to ₹ [•] lakhs
- Fresh Issue
- Up to 2,20,00,000 Equity Shares of face value of ₹ 2 each aggregating up to ₹ [•] lakhs
- Offer for Sale
- Not Applicable
- Price Band
- ₹ [●] per Equity Share (Floor Price) to ₹ [●] per Equity Share (Cap Price)
- Lot Size
- [●] Equity Shares of face value of ₹ 2 each and in multiples of [●] Equity Shares thereafter
- Face Value
- ₹ 2 each
Business Model
The company operates through a chain of multispeciality hospitals providing integrated secondary and tertiary healthcare services. Revenue is derived from inpatient department (IPD) and outpatient department (OPD) services across multiple medical specialities, including nephrology, cardiology, orthopaedics, gynaecology, trauma care, and general medicine. The company also operates pharmacies within its hospital premises.
Business Segments
Multispeciality hospital providing secondary and tertiary healthcare services
Multispeciality hospital operated by subsidiary
Partnership entity controlled by company providing multispeciality services
Partnership entity controlled by company for surgical services
Acquired multispeciality hospital and pharmacy
Acquired multispeciality and trauma center providing emergency and speciality care
Acquired multispeciality hospital in North Gujarat region
Treatment and care of admitted patients in hospital beds
Diagnostic and treatment services for non-admitted patients
Pharmacy, diagnostic imaging, laboratory and related healthcare services
Operates multi-speciality hospitals providing comprehensive healthcare services including emergency care, in-patient and out-patient services, diagnostic and imaging services, and surgical services
Hospitalization and inpatient medical services including surgeries, treatments, and intensive care
Outpatient consultation and diagnostic services
Surgical services provided across the hospital network including general surgery, laparoscopic surgery, orthopedic surgery, obstetrics and gynecology, and other specialties.
Super speciality surgical services including nephrology, urology, cardiology, neurology, oncology, gastroenterology, and other advanced specialties with focus on renal sciences and urology.
Integrated diagnostic services including pathology laboratory, radiology, imaging, and other diagnostic support services provided in-house at hospitals.
Operation of pharmacies including in-house pharmacy at hospitals and standalone medical stores providing medicines and related goods.
Includes inpatient (IPD) care, outpatient (OPD) care, and other medical services such as surgical procedures, diagnostic services, and emergency care
Sale of pharmaceutical products and related goods
Multi-specialty hospital providing inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care
Medical and Healthcare Services
Multi-specialty hospital providing inpatient and outpatient services
Clinical examinations, treatments, surgeries, room charges, nursing care, and related inpatient services
Physical examinations, consultations, treatments, procedures, and out-patient medical services
Income from training and other ancillary services
Inpatient and outpatient hospital services including nephrology, kidney transplant, and super-specialty medical care
SWOT Analysis
Strengths
- • Multi-specialty hospital network across central and south Gujarat with 490 beds across 7 hospitals(p.29)
- • Established presence in growing healthcare market with government health spending increasing(p.29)
- • Experienced promoter with deep medical expertise(p.49)
- • Growing inpatient and outpatient volumes(p.57)
- • Increasing bed occupancy rates(p.57)
- • Established presence in renal sciences with strong urology sub-specialization(p.148)
- • Right-sized, full-service hospitals in strategic locations with high return on capital(p.148)
- • Track record of operating and financial performance with growing profitability(p.148)
- • Strong weighted average RoNW of 38.72% (Proforma basis FY25-FY23)(p.150)
- • Ability to attract, train and retain quality medical professionals(p.148)
- • Strong profitability and returns on capital(p.207)
- • High return on equity and capital efficiency(p.157)
- • Healthy balance sheet with low debt burden(p.208)
- • Strong operational margins and efficiency(p.154)
- • Good bed occupancy rates and patient volumes(p.156)
- • Strategic acquisitions to expand service offerings(p.210)
- • Pre-eminence in renal sciences with established sub-specialties in urology(p.220)
- • Established six sub-specialties in urology department with high procedure volumes(p.220)
- • Asset-light hospital model reducing capital requirements(p.221)
- • Strong regional presence with understanding of local market nuances(p.221)
- • High individual/walk-in patient revenue demonstrating strong brand preference(p.220)
- • NABH accreditation demonstrating quality standards(p.224)
- • Experienced management with medical expertise and long operational history(p.218)
- • Established multi-specialty healthcare operations with experienced senior medical leadership(p.303)
- • Experienced founder with 30+ years in surgical practice(p.283)
- • Significant asset base and revenue generation from healthcare services(p.297)
- • Rapid growth in consolidated operations through acquisitions(p.322)
- • Multi-specialty healthcare operations with established infrastructure(p.373)
- • Strong profitability with consistent net profit margins above 35%(p.343)
- • Low leverage with debt-to-equity ratio of 0.13(p.343)
- • Strong debt service capability with DSCR of 6.75x(p.343)
- • Rapid asset growth from acquisitions and organic expansion(p.365)
- • High return on equity of 15.85% as of June 2025(p.343)
- • Improved liquidity with current ratio of 1.28(p.343)
- • Strong profitability growth trajectory(p.466)
- • Significant improvement in profit after tax(p.466)
- • Strong operational cash generation(p.467)
- • Demonstrated growth in revenue(p.472)
- • NABH accreditation for quality compliance(p.489)
Weaknesses
- • Heavy revenue concentration on Gujarat Kidney Hospital in Vadodara(p.46)
- • Geographic concentration risk with majority of hospitals in central Gujarat(p.46)
- • Reliance on leased properties with renewal risks for key hospitals(p.43)
- • Limited operating history and past performance may not be indicative of future results(p.42)
- • Incomplete acquisition financing with payment obligations outstanding(p.40)
- • Insurance coverage below 54% of asset value(p.47)
- • Dependence on promoter for business strategy and operations(p.49)
- • Unsecured loans from promoters that are recallable(p.52)
- • Limited experience in managing acquisitions(p.52)
- • High operating expenses and cost pressures(p.51)
- • Subsidiary with negative cash flows(p.65)
- • Shortage and retention challenges for nursing staff(p.53)
- • Majority of doctors are non-employees with high attrition(p.63)
- • High trade receivables and collection challenges(p.54)
- • Past regulatory and compliance violations(p.56)
- • Delayed statutory filings and payments(p.66)
- • Substantial outstanding secured borrowings requiring debt management(p.143)
- • Reliance on leased land for new hospital construction creating long-term tenure risk(p.141)
- • Recent acquisitions not yet fully integrated into financial statements for comparable periods(p.128)
- • Concentration of Promoter shareholding at 99.10% pre-Issue creates governance risk(p.113)
- • Relatively small scale compared to large hospital chains(p.157)
- • Limited geographic presence and concentration(p.210)
- • Heavy dependence on proforma financials reflecting acquisitions not yet fully integrated(p.157)
- • Lower EBITDA and PAT margins on proforma basis versus restated(p.154)
- • Substantial acquisition costs creating near-term integration risks(p.212)
- • Operational dependence on key medical professionals and consultant doctors(p.225)
- • Concentration of hospitals in central Gujarat region(p.218)
- • Significant acquisition-related debt and leverage(p.223)
- • Multiple related party transactions and potential conflicts of interest(p.252)
- • Regulatory dependence on multiple licenses and approvals(p.245)
- • High concentration of ownership and control with promoter Pragnesh Bharpoda(p.328)
- • Significant goodwill from acquisitions not deductible for tax(p.322)
- • Promoters involved in competing healthcare businesses(p.285)
- • Significant contingent income tax liability(p.337)
- • Trade receivables aging shows material old receivables(p.325)
- • Significant related party transactions and borrowings from promoters(p.340)
- • High dependence on unsecured borrowings from related parties (₹128.02 Lakhs)(p.356)
- • Significant goodwill of ₹713.09 Lakhs from acquisitions, subject to impairment risk(p.365)
- • Volatile profitability in pro forma statements with limited operational history(p.372)
- • Recent consolidation with newly acquired entities creates integration risk(p.375)
- • Limited operating history with company operational for only 42 days in FY 2023-24(p.343)
- • Negative equity in one subsidiary (Surya Hospital and ICU) with NCI of -₹52.65 Lakhs(p.350)
- • Significant reliance on borrowings for operations(p.468)
- • High leverage with restrictive debt covenants(p.477)
- • Pending consumer litigation with material claims(p.481)
- • Material litigation involving promoters(p.482)
- • Limited scale with concentration in two locations(p.489)
Opportunities
- • Acquisition of Parekhs Hospital to expand into Ahmedabad market(p.40)
- • Greenfield expansion with new women's healthcare hospital in Vadodara(p.41)
- • Investment in advanced robotics technology for orthopaedic services(p.43)
- • Consolidation through acquisition of Harmony Medicare Private Limited subsidiary stake(p.29)
- • Organic growth through general corporate purposes and unidentified acquisitions(p.29)
- • Expansion through acquisitions in western India markets(p.67)
- • Growth in super-specialty services and new technologies(p.55)
- • Leveraging IPO proceeds for hospital expansion(p.68)
- • Proposed acquisition of Parekhs Hospital (49 beds, 4 theatres) to expand Ahmedabad presence(p.122)
- • Acquisition of Ashwini Medical Centre expanding footprint to Anand with new super-specialties(p.125)
- • Expansion into women's healthcare with dedicated 50-bed hospital in Vadodara(p.128)
- • Introduction of advanced robotics (MAKO SmartRobotics System) for orthopaedic procedures(p.142)
- • Inorganic growth strategy with up to ₹[●] lakhs earmarked for unidentified acquisitions(p.145)
- • Large infrastructure gap and rising demand in Indian healthcare(p.201)
- • Expansion driven by growing non-communicable disease burden(p.180)
- • Aging population and rising demand for healthcare services(p.179)
- • Growing medical tourism market providing high-value patients(p.196)
- • Expansion in tier-2 and tier-3 markets with underpenetrated healthcare(p.197)
- • Increased health insurance penetration supporting hospital demand(p.195)
- • Government support and favorable healthcare spending policies(p.201)
- • Projected strong healthcare sector growth(p.205)
- • Expanding India's hospital sector with strong growth trajectory(p.218)
- • Strategic inorganic growth through acquisitions in central Gujarat(p.224)
- • Growth in non-communicable diseases and aging population driving healthcare demand(p.218)
- • Expanding specialties and capabilities in newly acquired hospitals(p.226)
- • Improving operational efficiencies through integration and economies of scale(p.225)
- • Underserved regional healthcare market in Gujarat with significant growth potential(p.221)
- • Expansion through acquisition of healthcare entities and consolidation strategy(p.322)
- • Diversification into multiple medical specialties(p.283)
- • Leveraging multi-specialty capabilities to enhance revenue growth(p.303)
- • Geographic expansion through acquisition of multiple hospitals across Gujarat and beyond(p.374)
- • Capacity expansion with proposed acquisition of Parekh's Hospital (100% stake for ₹7,900 Lakhs)(p.375)
- • Consolidation opportunity in Indian healthcare sector through strategic acquisitions(p.373)
- • Revenue synergies from integrated multi-specialty healthcare network(p.390)
- • Proposed capital infusion through IPO to fund acquisitions and debt reduction(p.375)
- • Expansion through acquisition of Harmony Medicare(p.471)
- • Growth through new hospital in Vadodara for women's healthcare(p.498)
- • Kidney transplant centre operational certification(p.491)
- • Diversified service capabilities across diagnostics and surgery(p.490)
Threats
- • Regulatory and approval risks for acquisition completion(p.40)
- • Construction delays and cost overruns for new hospital projects(p.40)
- • Regional economic and political disruptions in Gujarat(p.46)
- • Professional liability and medical negligence claims exceeding insurance coverage(p.47)
- • Attrition and retention challenges for healthcare professionals(p.47)
- • Healthcare professional availability and competition for talent(p.47)
- • Increasing regulatory complexity in healthcare(p.48)
- • Risk of losing patients due to doctor preferences(p.48)
- • Competition from established healthcare providers(p.64)
- • Pricing pressures from government health schemes and regulations(p.64)
- • Dependence on insurance company reimbursements and delays(p.54)
- • Equipment failures and maintenance costs(p.59)
- • Macroeconomic and seasonal variations in patient volumes(p.57)
- • Pandemic and public health emergencies(p.64)
- • Rising healthcare professional costs and compensation pressures(p.48)
- • Data security and privacy law compliance risks(p.58)
- • Acquisition of Parekhs Hospital subject to successful listing by January 31, 2026(p.123)
- • Unanticipated delays in construction approvals and implementation for new Vadodara hospital(p.141)
- • Cost escalation risks for civil, interior and furniture work with no firm purchase orders placed(p.142)
- • Delay risk in raising funds from Issue affecting payment to Ashwini Medical Centre sellers(p.126)
- • Healthcare sector regulatory and compliance risks including NABH accreditation requirements(p.127)
- • Competition from large established hospital chains with pan-India presence(p.204)
- • High capital intensity and long payback periods in hospital sector(p.206)
- • Shortage of qualified medical and nursing workforce(p.207)
- • High real estate and operational costs limiting expansion(p.206)
- • Regulatory and accreditation compliance burdens(p.184)
- • Rising lifestyle diseases increasing healthcare demand but straining capacity(p.181)
- • Dependence on imported medical equipment creating supply chain risks(p.206)
- • Highly competitive healthcare services industry with established players(p.235)
- • Extensive regulatory requirements and compliance obligations(p.237)
- • Dependence on government healthcare schemes and policy changes(p.220)
- • Drug price control regulations impacting pharmaceutical procurement(p.241)
- • Significant unorganized local healthcare competition(p.235)
- • Risk of trademark non-registration limiting brand protection(p.236)
- • Related party conflicts and acquisition arrangements with promoters(p.285)
- • Dependence on professional fees from related party doctors(p.339)
- • Significant borrowings and lease obligations(p.330)
- • Operating leverage exposure through business combinations with non-controlling interests(p.330)
- • Healthcare sector competition from established multi-specialty hospital chains(p.373)
- • Regulatory changes in healthcare pricing and licensing requirements(p.345)
- • Input cost inflation affecting medical supplies and equipment expenses(p.390)
- • Personnel dependency with high employee benefit costs(p.369)
- • Technology obsolescence risk in medical equipment with 5-15 year useful lives(p.396)
- • Integration risks from multiple recent acquisitions with different operational models(p.375)
- • Macroeconomic sensitivity affecting patient volumes and healthcare spending(p.390)
- • Healthcare industry regulation and compliance requirements(p.487)
- • Expiry of licenses and regulatory approvals requiring renewal(p.500)
- • Rising debt servicing obligations with restrictive covenants(p.477)
- • Dependence on key credit facilities with potential recall risk(p.478)
- • Market risk exposure from currency and interest rate fluctuations(p.469)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter | 52.92% | — |
| Dr. Bhartiben Pragnesh Bharpoda | Promoter | 15.39% | — |
| Dr. Yashwantsingh Motisinh Bharpoda | Promoter | 15.39% | — |
| Anitaben Yashwantsinh Bharpoda | Promoter | 15.39% | — |
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter | — | — |
| Dr. Bhartiben Pragnesh Bharpoda | Promoter | — | — |
| Dr. Yashwantsingh Motisinh Bharpoda | Promoter | — | — |
| Anitaben Yashvantsinh Bharpoda | Promoter | — | — |
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter | 52.92% | — |
| Dr. Yashwantsingh Motisingh Bharpoda | Promoter | 15.39% | — |
| Anitaben Yashvantsinh Bharpoda | Promoter | 15.39% | — |
| Dr. Bhartiben Pragnesh Bharpoda | Promoter | 15.39% | — |
| Nikita Yashvantsinh Bharpoda | Promoter Group | Negligible | — |
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter/Chairman and Managing Director | — | — |
| Dr. Pragnesh Yashwantsingh Bharpoda | Promoter/Chairman and Managing Director | 52.92% | — |
| Dr. Bhartiben Pragnesh Bharpoda | Promoter/Whole-time Director | 15.39% | — |
| Anitaben Yashvantsinh Bharpoda | Promoter/Non-Executive Director | 15.39% | — |
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter | 52.92% | — |
| Dr. Bhartiben Pragnesh Bharpoda | Promoter | 15.39% | — |
| Dr. Yashwantsingh Motisinh Bharpoda | Promoter | 15.39% | — |
| Anitaben Yashvantsinh Bharpoda | Promoter | 15.39% | — |
| Pragnesh Bharpoda | Promoter/Director | — | — |
| Anitaben Bharpoda | Promoter/Director | — | — |
| Parekhs Hospital Private Limited shareholders | Promoter | — | — |
| Dr. Pragnesh Yashwantsinh Bharpoda | Promoter | — | — |
| Dr. Yashwantsingh Motisinh Bharpoda | Promoter | — | — |
Leadership
Dr. Pragnesh Yashwantsinh Bharpoda · Chairman and Managing Director
Dr. Bhartiben Pragnesh Bharpoda · Whole-time Director
Bhavikaben Mitesh Patel · Chief Financial Officer
Niki Paresh Tiwari · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.